• Contact Us

  • Pipeline
    Lynovex (NM001) Nylexa (NM002) Novexatin (NP213) NP339 NP432

  • Technology

  • Therapeutic Focus

  • About Us
    Board and Management Investors Corporate Social Responsibility

  • News and Events
  • Follow
  • Follow
  • Follow
  • News and Events
  • About Us
    • Board and Management
    • Investors
    • Corporate Social Responsibility
  • Therapeutic Focus
  • Technology
  • Pipeline
    • NM001 (Lynovex®)
    • NM002 (Nylexa®)
    • NP213 (Novexatin®)
    • NP339
    • NP432
  • Contact Us

Lynovex Poster Presentations at 33rd North American Cystic Fibrosis Conference (NACFC)

by novabioticsadm1n | Mar 19, 2019 | 2019, Press Releases

Date posted: March 19, 2020 Three Posters on New Lynovex Preclinical and Clinical Data to be presented at NACFC, 31st October to 2nd November 2019, Nashville Tennessee. Dr Douglas Fraser-Pitt will present three posters on Thursday 31st October 2019...

NovaBiotics Prize awarded at Robert Gordon University Ceremony

by novabioticsadm1n | Mar 19, 2019 | 2019, Press Releases

Date posted: March 19, 2020 Congratulations to Amanda Nicolson, winner of the Novabiotics Prize: Best IBMS Registration Training Portfolio at the 11th July 2019 prize-giving ceremony held at Robert Gordon University, Garthdee Campus in Aberdeen. Categories Press...

NovaBiotics to present new data on their novel Cystic Fibrosis drugs at the European CF Society’s Annual Conference

by novabioticsadm1n | Mar 19, 2019 | 2019, Press Releases

Date posted: March 19, 2020 NovaBiotics will present new efficacy data for their Lynovex® Cystic Fibrosis (CF) drug candidates at the European CF Society Conference (ECFS) in Liverpool, UK, June 5th-8th. ECFS is a major international event and provides a forum for all...

NovaBiotics presenting new data at European Cystic Fibrosis Conference

by novabioticsadm1n | Mar 19, 2019 | 2019, Press Releases

Date posted: March 19, 2020 NovaBiotics are pleased to announce that we will be participating in the 42nd European Cystic Fibrosis Conference (ECFS); 5-8 June 2019, Liverpool. Our team will be presenting exciting new data on the antimicrobial mechanism of action,...

Novexatin manuscript published in Antimicrobial Agents & Chemotherapy Journal

by novabioticsadm1n | Mar 19, 2019 | 2019, Press Releases

Date posted: March 19, 2020 The manuscript is entitled “Improved Methods for Assessing Therapeutic Potential of Antifungal Agents Against Dermatophytes and their Application in the Development of NP213, a Novel Onychomycosis Therapy Candidate”. The...

Recent Posts

  • Just when we thought things were getting better…..
  • CARE CF 1 oral Lynovex clinical trial data published
  • NovaBiotics in the press
  • As world antimicrobial awareness week gets underway, our CEO shares her thoughts on the near-term outlook for antimicrobials: the economic case aligning with innovation
  • Why, in the current crisis we still need more effective, proven treatments for COVID-19

Recent Comments

  • bahis on NovaBiotics secures £1m funding for COVID 19 project
  • NovaBiotics secures £1m COVID-19 Innovate funding for Nylexa clinical development - Tricapital on NovaBiotics secures £1m funding for COVID 19 project
  • NovaBiotics secures £1m COVID-19 Innovate funding for Nylexa clinical development - Tricapital on OBE for NovaBiotics’ CEO in the Queen’s Birthday Honours List

NovaBiotics Ltd
Silverburn Crescent
Bridge of Don
Aberdeen
AB23 8EW, UK

Tel:+44 (0)1224 711377

Registered Company
No. SC272344

NovaBiotics Inc
One Boston Place,
Suite 2600,
Boston
MA, 02108

Tel:+1 866 259 4527

NovaBiotics
90 Upper George's Street,
Dun Laoghaire,
Co. Dublin,
A96 R8R9

Tel:+353 1 2712605

Registered Company
No. 642058

News and Events

About Us

Therapeutic Focus

Technology

Pipeline

Contact Us